Sanofi, Re­gen­eron’s Dupix­ent scores an­oth­er in­di­ca­tion with first-ever ap­proval for nodu­lar skin dis­or­der

Sanofi chief ex­ec­u­tive Paul Hud­son told in­vestors ear­li­er this year that the Big Phar­ma was go­ing to em­pha­size its sales king­pin Dupix­ent mov­ing for­ward.

He wasn’t jok­ing — the megablock­buster drug and sales king, record­ing just shy of $2 bil­lion in sales this past quar­ter, has now of­fi­cial­ly se­cured its fifth in­di­ca­tion from the FDA.

Sanofi and Re­gen­eron, who joint­ly work on Dupix­ent de­vel­op­ment and com­mer­cial­iza­tion, an­nounced the new de­vel­op­ment on Thurs­day, say­ing that the FDA gave the all-clear to Dupix­ent to treat pa­tients with pruri­go nodu­laris, a rare au­toim­mune dis­or­der char­ac­ter­ized by a per­sis­tent, se­vere itch — and al­so vi­su­al­ized by hard, ex­treme­ly itchy bumps known as nod­ules that form on the skin. The FDA not­ed in its an­nounce­ment that it is the agency’s first ap­proval for the dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER